Hepatitis B immune reconstitution syndrome in a patient with HIV infection

Melanie-Anne A John; Bernadett I Gosnell; Thandekile C Manzini; Prastistadevi Ramdial; Mahomed-Yunus S Moosa

doi:10.1177/0956462416628320

Hepatitis B immune reconstitution syndrome in a patient with HIV infection

Int J STD AIDS. 2016 Oct;27(12):1126-1129. doi: 10.1177/0956462416628320. Epub 2016 Jan 13.

Authors

Melanie-Anne A John¹, Bernadett I Gosnell², Thandekile C Manzini², Prastistadevi Ramdial³, Mahomed-Yunus S Moosa²

Affiliations

¹ Department of Infectious Diseases, UKZN, South Africa Enhancing Care Foundation, South Africa [email protected].
² Department of Infectious Diseases, UKZN, South Africa Department of Infectious Disease, King Edward VIII Hospital, UKZN, South Africa.
³ Department of Anatomical Pathology, Inkosi Albert Luthuli Hospital, National Health Laboratory Services, South Africa.

PMID: 26769756
DOI: 10.1177/0956462416628320

Abstract

South Africa has a high rate of HIV and hepatitis B co-infection. The national HIV treatment guidelines include anti-retrovirals that treat both viruses. We describe a HIV-positive patient who presented with liver histology-confirmed hepatitis B immune reconstitution inflammatory syndrome whilst on a regimen containing lamivudine and tenofovir.

Keywords: AIDS; HIV; co-infection; hepatitis B virus; immune reconstitution inflammatory syndrome.

Publication types

Case Reports

MeSH terms

Adult
Anti-HIV Agents / therapeutic use
Antiretroviral Therapy, Highly Active
Coinfection / virology
HIV Infections / complications*
HIV Infections / drug therapy
HIV Infections / virology
HIV-1 / drug effects
Hepatitis B / complications*
Hepatitis B / drug therapy
Hepatitis B / virology
Hepatitis B virus / drug effects
Hepatitis B virus / genetics
Humans
Immune Reconstitution Inflammatory Syndrome / complications*
Immune Reconstitution Inflammatory Syndrome / drug therapy
Lamivudine / administration & dosage
Lamivudine / therapeutic use
Treatment Outcome

Substances

Anti-HIV Agents
Lamivudine